Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

Earlier this month, the US government announced a US$500 million (£377 million) investment to accelerate research into ...

Hinge Health Inc. and a group of investors raised $437 million in the digital physical therapy provider’s US initial public ...